Background/Aims: To investigate the etiology of hypogonadism in women with Prader-Willi Syndrome (PWS). Methods: Ten women aged 23 ± 5.5 years with PWS and 10 age- and BMI-matched controls were included. Blood samples were drawn and abdominal ultrasounds were performed on days 2–4 of spontaneous cycles or at random from amenorrheic women. Anti-Müllerian hormone (AMH), inhibin B (INB), gonadotropins, sex steroids, TSH, prolactin, ovarian volume and antral follicle count (AFC) in PWS women were compared with results from controls and the reference ranges. Results: Compared to controls, PWS women had lower INB (mean ± SD = 17.6 ± 12.8 pg/ml vs. 110.6 ± 54.5; p = 0.0002) and AMH levels (1.18 ± 0.86 ng/ml vs. 3.53 ± 2.42; p = 0.01). INB levels were exceptionally low in all PWS women, but individual AMH levels overlapped with the levels in the controls. Ovarian volume (mean ± SD = 3.7 ± 2.3 ml vs. 30.5 ± 28.8; p = 0.03) and AFC (6.4 ± 6.9 vs. 14.0 ± 8.2; p = 0.01) were lower in the PWS group compared to the controls. Three PWS patients had abnormally high follicle-stimulating hormone levels, while only 1 had hypogonadotropic hypogonadism. Conclusions: Our results suggest a unique follicular stage-specific insult in women with PWS. Thus, primary ovarian dysfunction is a major component of hypogonadism in PWS.

1.
Cassidy SB: Prader-Willi syndrome. J Med Genet 1997;34:917–923.
2.
Wattendorf DJ, Muenke M: Prader-Willi syndrome. Am Fam Physician 2005;72:827–830.
3.
Goldstone AP: Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004;15:12–20.
4.
Benarroch F, Hirsch HJ, Genstil L, Landau Y, Gross-Tsur V: Prader-Willi syndrome: medical prevention and behavioral challenges. Child Adolesc Psychiatr Clin N Amer 2007;16:695–708.
5.
Glaser B, Hirsch HJ: Genetics for Endocrinologists: The Molecular Genetic Basis of Endocrine Disorders. London, Remedica Publishing, 2000, pp 70–73.
6.
Swaab DF: Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997;423:50–54.
7.
Crinò A, Schiaffini R, Ciampalini P, Spera S, Beccaria L, Benzi F, Bosio L, Corrias A, Gargantini L, Salvatoni A, Tonini G, Trifirò G, Livieri C; Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology (SIEDP): Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003;162:327–333.
8.
Eiholzer U, l’Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Grüters A, Simoni M: Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab 2006;91:892–898.
9.
Burman P, Ritzén EM, Lindgren AC: Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787–799.
10.
Eiholzer U, Grieser J, Schlumpf M, l’Allemand D: Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007;68:178–184.
11.
Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H: Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 2000;12:3101–3110.
12.
Jeffcoate WJ, Laurance BM, Edwards CR, Besser GM: Endocrine function in the Prader-Willi syndrome. Clin Endocrinol (Oxf) 1980;12:81–89.
13.
Akefeldt A, Törnhage CJ, Gillberg C: A woman with Prader-Willi syndrome gives birth to a healthy baby girl. Dev Med Child Neurol 1999;41:789–790.
14.
Schulze A, Mogensen H, Hamborg-Petersen B, Graem N, Ostergaard JR, Brøndum-Nielsen K: Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. Acta Paediatr 2001;90:455–459.
15.
Weenen C, Laven JS, von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP: Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83.
16.
Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J: Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323–327.
17.
Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401–1405.
18.
Messinis IE: Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod Update 2006;12:557–571.
19.
Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT: Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571–576.
20.
Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C: Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737–743.
21.
Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ: Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005;20:3178–3183.
22.
Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Müller J, Skakkebaek NE: Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab 2000;85:1634–1640.
23.
Crisosto N, Codner E, Maliqueo M, Echiburú B, Sánchez F, Cassorla F, Sir-Petermann T: Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739–2743.
24.
Codner E, Mook-Kanamori D, Bazaes RA, Unanue N, Sovino H, Ugarte F, Avila A, Iñiguez G, Cassorla F: Ovarian function during puberty in girls with type 1 diabetes mellitus: response to leuprolide. J Clin Endocrinol Metab 2005;90:3939–3945.
25.
Speroff L, Fritz MA: Clinical Gynecologic Endocrinology and Infertility, ed 7. Philadelphia, Lippincott Williams & Wilkins, 2005, pp 1304.
26.
Roberts VJ, Barth S, el-Roeiy A, Yen SS: Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 1993;77:1402–1410.
27.
Wachs DS, Coffler MS, Malcom PJ, Chang RJ: Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 2007;92:1871–1874.
28.
Hamilton CR Jr, Scully RE, Kliman B: Hypogonadotropinism in Prader-Willi syndrome. Induction of puberty and sperm altogenesis by clomiphene citrate. Am J Med 1972;52:322–329.
29.
McGuffin WL Jr, Rogol AD: Response to LH-RH and clomiphene citrate in two women with the Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab 1975;41:325–331.
30.
Linde R, McNeil L, Rabin D: Induction of menarche by clomiphene citrate in a fifteen-year-old girl with the Prader-Labhart-Willi syndrome. Fertil Steril 1982;37:118–120.
31.
de Lind van Wijngaarden RF, Otten BJ, Festen DA, Joosten KF, de Jong FH, Sweep FC, Hokken-Koelega AC: High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:1649–1654.
32.
Treasure JL, Wheeler M, King EA, Gordon PA, Russell GF: Weight gain and reproductive function: ultrasonographic and endocrine features in anorexia nervosa. Clin Endocrinol (Oxf) 1988;29:607–616.
33.
Jonard S, Pigny P, Jacquesson L, Demerle-Roux C, Robert Y, Dewailly D: The ovarian markers of the FSH insufficiency in functional hypothalamic amenorrhoea. Hum Reprod 2005;20:101–107.
34.
van Elburg AA, Eijkemans MJ, Kas MJ, Themmen AP, de Jong FH, van Engeland H, Fauser BC: Predictors of recovery of ovarian function during weight gain in anorexia nervosa. Fertil Steril 2007;87:902–908.
35.
Harwood K, Vuguin P, DiMartino-Nardi J: Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 2007;68:209–217.
36.
Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN: The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;23:952–957.
37.
Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A: Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res 2007;68:83–90.
38.
Mapendano CK, Kishino T, Miyazaki K, Kondo S, Yoshiura K, Hishikawa Y, Koji T, Niikawa N, Ohta T: Expression of the Snurf-Snrpn IC transcript in the oocyte and its putative role in the imprinting establishment of the mouse 7C imprinting domain. J Hum Genet 2006;51:236–243.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.